Michael Kantrowitz, Piper Sandler chief investment strategist, joins 'The Exchange' to discuss why higher rates pose the biggest risks to markets and more.

On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...

Piper Sandler raised the firm’s price target on Arhaus (ARHS) to $15 from $14 and keeps an Overweight rating on the shares ...

Piper Sandler Companies is gaining traction with a recovering market. Find out why PIPR stock is becoming an attractive ...

Piper Sandler upgraded Par Pacific (PARR) to Overweight from Neutral with a price target of $25, up from $23. The company’s ...

Piper Sandler dipped into the beverage sector on Tuesday by issuing new Overweight ratings on Coca-Cola (NYSE:KO) and PepsiCo ...

Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

Despite recent share appreciation, Piper Sandler believes there is still significant upside for Kenvue. “Though shares have ...

Piper Sandler downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight with an unchanged price target of $10 following Roche’s announced acquisition for $9 per share in cash and $4 per ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...